APM (Aptorum Group) Inventories, Other : $0.00 Mil (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Aptorum Group's other inventories for the quarter that ended in Jun. 2024 was $0.00 Mil.

Aptorum Group's annual other inventories declined from Dec. 2021 ($0.04 Mil) to Dec. 2022 ($0.03 Mil) and declined from Dec. 2022 ($0.03 Mil) to Dec. 2023 ($0.00 Mil).

Aptorum Group Inventories, Other Historical Data

The historical data trend for Aptorum Group's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Inventories, Other Chart

Aptorum Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Other

Get a 7-Day Free Trial

0.03

0.04

0.03

Aptorum Group Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Inventories, Other	Get a 7-Day Free Trial									0.03	0.03	-	-	-

Aptorum Group Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Aptorum Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Inventories, Other

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.aptorumgroup.com

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.